Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F12%3A00057708" target="_blank" >RIV/00216224:14110/12:00057708 - isvavai.cz</a>
Alternative codes found
RIV/65269705:_____/12:#0001913
Result on the web
<a href="http://dx.doi.org/10.3109/10428194.2011.652106" target="_blank" >http://dx.doi.org/10.3109/10428194.2011.652106</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3109/10428194.2011.652106" target="_blank" >10.3109/10428194.2011.652106</a>

Result language
angličtina
Original language name
Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma
Original language description
The introduction of novel drugs (thalidomide, lenalidomide [immunomodulatory drugs; IMiDs] and bortezomib) optimistically changed the outcome of patients with multiple myeloma (MM) in terms of progressionfree and overall survival when compared to conventional chemotherapies.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)

Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)